NASDAQ · KLRA
Kailera Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for KLRA: Nov 11, 2026
Kailera Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.55.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.55 | $-0.79 | $-2.72 | 3 |
| Dec 2026 | $-1.10 | $-0.95 | $-1.34 | 3 |
| Mar 2027 | $-1.45 | $-1.45 | $-1.45 | 1 |
| Jun 2027 | $-1.48 | $-1.48 | $-1.48 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · The Motley Fool- BNK Invest · Oct 2, 4:34 PM EDTOversold Conditions For Kailera Therapeutics (KLRA)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- RTTNews · Oct 1, 10:22 AM EDTKailera Presents Phase 1 Data For Ribupatide In Weight Management; Stock Down(RTTNews) – Kailera Therapeutics Inc. (KLRA), a clinical-stage biotechnology company, on Thursday reported promising results from the Phase 1 trial for GLP-1/GIP antagonist Ribupatide, developed for treating obesity. The data were presented at the 62nd Annual Meeting of the Europ
- The Motley Fool · Sep 30, 7:30 PM EDTNovo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to BuyNovo Nordisk could strengthen its obesity pipeline by buying out Kailera Therapeutics and Viking Therapeutics.
- The Motley Fool · Aug 16, 4:20 PM EDT2 GLP-1 Stocks That Could Double Your Money by 2031Viking Therapeutics and Kailera Therapeutics have promising GLP-1 candidates.
- The Motley Fool · Jul 15, 1:20 AM EDT2 Beaten-Down GLP-1 Stocks to Buy on the DipNovo Nordisk and Kailera Therapeutics have attractive GLP-1 pipelines.
- The Motley Fool · Jul 2, 5:20 PM EDTPfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma GiantPfizer has the funds to acquire more companies.
- The Motley Fool · Jun 16, 3:50 AM EDT3 Under-the-Radar Stocks to Buy and Hold for a DecadeThese three innovative biotechs are developing products in markets with high unmet needs.
- The Motley Fool · Jun 12, 2:50 AM EDTParabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?Parabilis and another recent IPO stock each raised more than Moderna — which had previously been the biggest biotech IPO.
- The Motley Fool · May 16, 10:50 AM EDTIs Kailera Therapeutics a Buy After Its Sizzling IPO?The GLP-1 drug market could be worth $190 billion by 2035.
- The Motley Fool · Apr 27, 11:01 AM EDTA Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million500,000 shares were acquired for a transaction value of $8.00 million on April 20, 2026.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Kailera Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.